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Abstract  
Systemic Lupus Erythematosus (SLE) is an autoimmune, inflammatory disease that mainly affects 
women. The prognosis of SLE has improved dramatically, but mortality rates are still higher than in the 
general population. With the improved general prognosis, cardiovascular disease (CVD) has emerged as a 
major cause of morbidity and mortality among SLE patients. Previous studies have demonstrated that the 
development of atherosclerosis is accelerated in SLE, and have identified a set of traditional and non-
traditional risk factors that characterize SLE patients with CVD. Nevertheless, many unsolved issues with 
respect to SLE related CVD remain. The general aim of this thesis was to investigate risk factors for 
manifest CVD and for cardiovascular mortality (CVM) in SLE, with special focus on traditional risk 
factors, lupus phenotype, inflammatory and endothelial biomarkers, autoantibodies and genetic 
predisposition.       
 In the first paper, we prospectively studied traditional and non-traditional risk factors for 
the development of the first cardiovascular event (CVE) in 182 SLE patients with a follow-up time of 8 
years. 24(13%) patients had a first event. We demonstrated that of the traditional risk factors, only age 
and smoking predicted the first CVE. Additionally, antiphospholipid antibodies (aPL), endothelial 
biomarkers, represented by soluble vascular cell adhesion molecule 1(sVCAM-1), and absence of 
thrombocytopenia were independent predictors of CVE. Thus, activation of the endothelium and the 
coagulation system are important features in SLE-related CVD and the importance to advocate smoking 
cessation among SLE patients is underscored    
 In the second paper, we prospectively investigated causes of mortality and risk factors for 
overall mortality and CVM in a cohort of 208 SLE patients, with a follow-up time of 12 years. We also 
evaluated Systematic coronary risk evaluation (SCORE, tool for evaluating the 10 year risk for 
cardiovascular death in the age span 40-65 years, based on traditional risk factors) in this population. 
Cystatin C, a sensitive measure of renal function, in addition to traditional and non-traditional risk 
factors, were evaluated as risk factors. 42 patients died, 48 % of which were due to CVM. Age, previous 
arterial events and high cystatin C levels were the strongest predictors for overall mortality and for CVM. 
After adjusting for these three variables, smoking, sVCAM-1 and high sensitiviy C-reactive protein 
(hsCRP) predicted CVM. SCORE estimated 4 but we observed 9 cases of CVM, a non-significant 
difference. We conclude that except for smoking, traditional risk factors are less important than cystatin 
C, endothelial and inflammatory biomarkers as predictors of CVM in SLE patients. 
 In the third paper, we investigated whether a risk allele for SLE in the signal transducer 
and activator of transcription factor 4 gene (STAT4) was associated with vascular events or presence of 
antiphospholipid antibodies (aPL). A total of 578 unrelated SLE patients (424 from mid-Sweden and 154 
from southern-Sweden) were included in a cross-sectional design. Occurrence of previous cardiovascular 
events and aPL were tabulated. Matched controls (N=651) were genotyped as a comparison. The results 
demonstrate that the STAT4 risk allele was associated with ischemic cerebrovascular disease (ICVD), 
with a dose-dependent relationship between ICVD and number of risk alleles. The risk allele was 
furthermore associated with the presence of two or more aPLs, also in a dose-dependent manner. The 
association remained after adjustment for known traditional risk factors. We conclude that patients with 
the STAT4 risk allele have an increased risk of ICVD. Our results imply that genetic predisposition is an 
important risk factor for ICVD in SLE patients, and that aPL may be one underlying mechanism. 
 In the fourth paper, we evaluated the potential association between smoking and aPL. 367 
SLE patients were investigated in a cross-sectional study. Occurrence of aPL (anticardiolipin (aCL) IgG 
and IgM, anti-β2 glycoprotein-1 IgG (aβ2GP1 IgG), lupus anticoagulant (LAC)) and smoking habits 
(never, ever, former, current) were tabulated. Never smoking was used as reference in all calculations. In 
multivariable models, adjusted for age, sex and age at disease onset, aCL and aβ2GP1 of the IgG isotype 
and LAC were associated with ever smoking, this association seemed to be driven mainly by the former 
smoking group. Our results demonstrate that smoking is associated with pro-thrombotic aPL in SLE 
patients, though we can not from this study draw firm conclusions about the temporal relationship 
between exposure to smoking and occurrence of aPL. Further studies are warranted to investigate the 
mechanisms behind these observations.     
 In prospective studies we have demonstrated that in particular smoking, systemic 
inflammation, endothelial activation and aPL are major risk factors for SLE related CVD and CVM. 
Furthermore, genetic predisposition, in our studies represented by a STAT4 SLE risk allele, contributes to 
the high risk of ICVD and to the occurrence of aPL, a possible underlying pathogenic mechanism. Finally 
we demonstrate that smoking, known to have unfavorable effects on the immune system and to 
significantly increase cardiovascular risk in SLE patients, is also associated with pro-thrombotic aPL in 
patients with SLE. Thus in SLE smoking stands out as the most important of the traditional risk factors 
with potential influence also on lupus related risk factors such as aPL.  
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Abbreviations 
ACR: American College of Rheumatology     
aCL: anticardiolipin antibodies    
ANA: Antinuclear Antibodies     
aβ2GP1: anti-β2 glycoprotein 1      
anti-dsDNA: antibodies to double stranded DNA     
aSSA/B: anti-Sjögrens syndrome A/B      
anti-oxLDL: antibodies aganist oxLDL      
aPL: antiphospholipid antibodies   
APS: antiphospholipid syndrome      
C: complement component    
CAC: coronary artery calcium      
CAD: coronary artery disease    
CVD: cardiovascular disease     
CVE: cardiovascular event                       
CVM: cardiovascular mortality      
FMD: flow mediated dilation     
GFR: glomerular filtration rate     
HDL: high density lipoprotien       
HLA: humal leukocyte antigen      
hsCRP: high sensitivity C- reactive protein      
ICAM-1: inter cellular adhesion molecule 1     
ICVD: ischaemic cerebrovascular disease     
IFN: interferon               
IHD: ischemic heart disease             
IL: interleukin         
IPVD: ischaemic peripheral vascular disease      
IMT: intima media thickness                 
LAC: lupus anticoagulant       
LDL: low density lipoprotein      
Lp(a): Lipoprotein a       
LPL: lipoprotein lipase       
MBL: mannose binding lectin      
MI: myocardial infarction      
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NK cell: natural killer cell     
oxLDL: oxidized LDL       
PON: paraoxonase     
RNP: Ribonucleoprotein       
SLAM: Systemic lupus activity measure     
SLE: Systemic Lupus Erythematosus      
SLICC: Systemic Lupus International Collaboration Clinics   
SNP: single-nucleotide polymorphism    
SMC: smooth muscle cell      
SMR: Standardized mortality ratio      
STAT4: Signal Transducer and activator of Transcription    
TG: triglycerides       
Th cell: T helper cell       
TIA: transitoric ischaemic attack      
TLR: toll like receptor       
TNF: tumor necrosis factor     
Treg: regulatory T cell       
(s)VCAM-1: soluble Vascular Cell Adhesion Molecule 1    
VLDL: very LDL       
vWf: von Willebrand factor  
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Systemic Lupus Erythematosus 
 
Introduction and historical background 
Systemic Lupus Erythematosus (SLE) is an autoimmune, inflammatory disease that can 
affect almost any organ. It is characterized by production of autoantibodies, immune 
complex formation and deposition that can lead to tissue injury. It manifests in many 
diverse clinical and serological patterns and has an unpredictable course.   
Historically, the term lupus (latin for wolf) was used in the 12th century to describe all 
kinds of dermatological lesions. In 1845, von Hebra described the typical butterfly rash, 
the erythema, over the mid-face. A few years later, in 1852, the term lupus 
erythematosus was introduced by Cazenave(1). The systemic nature of the disease was 
recognized in 1872, when Kapozi described it´s disseminated features(2). This was 
further developed by Osler in the late 1890s, who introduced nephritis and vasculitis as 
manifestations of lupus(3). The modern period began in 1949 with the discovery of the 
LE cell (the lupus erythematosus cell) in the bone marrow of SLE patients(4). First 
recognized as pathognomonic for SLE, it has later been shown to be present in other 
autoimmune conditions as well. The development of immunofluourescent techniques in 
1957 allowed the detection of antinuclear antibodies in clinical practice. This 
immunological test, further sharpened by the introduction of anti-DNA antibodies in 
1957, are still important tools for diagnosing SLE. 
 
Clinical features and classification criteria 
SLE is a chronic inflammatory disorder, which has a varied clinical course in different 
patients. It can be mild, only affecting a limited number of organs, or dramatic with life-
threatening involvement of multiple organs. Among the organs most often affected are 
joints, skin, kidneys, serous membranes, nervous system, blood elements, blood vessels 
and lungs. General symptoms like malaise, fever, and fatigue are all common. 
Except for various clinical manifestations, lupus is characterized by production of an 
array of autoantibodies. In fact, over 100 autoantibodies have been described(5). 
Antinuclear antibodies (ANA) are the hallmark of SLE, over 90% of patients are ANA 
positive. Antibodies to double-stranded DNA (anti-dsDNA) and the Smith (Sm) antigen 
are highly specific for SLE. Other autoantibodies that are studied in clinical practice 
include Sjögrens syndrome A and B antibodies (aSSA, aSSB), anti-ribonuclein (aRNP) 
antibodies, nucleosome antibodies and antiphospholipid antibodies (aPL). Some of 
these antibodies are reported to be associated with flares or specific organ involvement, 
such as anti-dsDNA with nephropathy, aSSA/aSSB with keratoconjunctivitis sicca, and 
aRNP with Raynaud´s phenomenon.  
The complexity of SLE becomes evident by studying the classification criteria for SLE 
provided by the American College of Rheumatology (ACR)(Table 1). These criteria 
were first published in 1971 and revised by Tan 1982(6). They include 9 clinical and 2 
immunological criteria, and according to them, a definite SLE diagnosis is present if the 
patient has four or more of the eleven criteria. In 1997, modifications were made, 
including aPL as a criterion(7) . Implementation of this modification would change the 
population of SLE patients, however, the criteria adapted by Tan et al are still the most 
commonly used. The classification criteria are mainly made for research purposes, and 
are not diagnostic of SLE. 
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Table 1. The 1982 American College of Rheumatology Criteria for Classification of 
SLE 
1. Malar rash Fixed erythema, flat or rised, over the 
malar eminences 
2. Discoid rash Erythematosus raised patches with 
adherent keratotic scaling and follicular 
plugging 
3. Photosensitivity Exposure to ultraviolet light causes rash 
4. Oral ulcers Includes oral and nasopharyngeal observed 
by a physician 
5. Arthritits Non-erosive arthritis involving peripheral 
joints, characterized by tenderness, 
swelling, or effusion 
6. Serositis Pleuritis or pericarditis, documented by 
ECG or rub or evidence of effusion 
7. Renal disorder Proteinuria >0.5 g/d or 3+, or cellular casts 
8. Neurologic disorder Seizures or psychosis without other causes 
9. Hematologic disorder Hemolytic anemia or leukopenia 
(<4000/L) or lymphopenia (<1500/L) or 
thrombocytopenia (<100,000/L) in the 
absence of offending drugs 
10. Immunologic disorder Positive LE cell preparation or anti dsDNA 
or anti-Sm antibodies or false positive 
VLDR, detectable aPLs or LAC* 
11. Anti-nuclear antibodies An abnormal titer of ANA by 
immunofluorescence or an equivalent 
assay at any point in time in the absence of 
drugs known to induce ANAs 
If four of these criteriae are present at any time during the cause of the disease, a diagnosis of SLE can 
be made with 98% specificity and 97% sensitivity. Source: (6). * detectable aPL or LAC was added in 
1997(7). Sm: the Smith antigen, LE: lupus erythematosus cell, VLDR: Veneral Disease Research 
Laboratory, ANA: anti-nuclear antibodies, aPLs: antiphospholipid antibodies, LAC: lupus anticoagulant 
activity 
  
Estimations of disease activity and damage 
The course of SLE is variable and mostly unpredictable. Several instruments have been 
developed for the assessment of disease activity and clinical response to treatment. The 
most commonly used are SLEDAI (SLE Disease Activity Index; over the last ten 
days)(8), SLAM(Systemic Lupus Erythematosus Activity Measure; activity over the 
last month)(9), and BILAG (British Isles Lupus Assessment Group)(10). SLICC 
(Systemic Lupus International Collaboration Clinics) (11) is a well established damage 
index, demonstrated to be useful in evaluating long term outcome.    
 
Epidemiology 
SLE is a fairly rare disease, but incidence and prevalence figures are difficult to 
compare because epidemiological studies may differ by sampling and recruitment 
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methodologies used. Incidence rates of SLE range from approximately 1 to 10 per 
100,000 person-years and prevalence generally range from 20 to 70 per 100,000(12). In 
a relatively recent study from southern Sweden, the prevalence was 68/100000 with an 
annual incidence of 4.8/100000(13). SLE predominately affects women of reproductive 
age, with a gender difference favouring women over men of 9:1(12). In the 1950s, the 
estimated 5-year survival in lupus was less than 50%(14) whereas recent studies report a 
5-year survival over 90%(15, 16). Nevertheless, the mortality rate in SLE still exceeds 
that of the general population(17, 18). Death related to lupus activity and infections has 
decreased over time, but still contribute to mortality(19, 20), especially in developing 
countries(21, 22). However, cardiovascular mortality (CVM) has not declined(23) in 
SLE. A slight increased standardized mortality ratio (SMR) due to vascular diseases has 
been reported(24), and death from cardiovascular disease (CVD) accounts for between 
6% and 76% in different studies(13, 25). (Table 2) 
 
Table 2. Causes of mortality, and where available also SMR*, in a selection of cohort studies of 
SLE patients 
Reference Study 
period 
CVD% SLE(active 
or 
endstage 
disease)% 
Infection% Malignancy% SMR Country 
Dubois et al 
1974(26) 
1950-
1963 
9 57 15 4   USA 
Urowitz et al 
1976(27) 
1970-
1974 
45 18 36     Canada 
Wallace et al 
1981(28) 
1950-
1980 
18 34 21 3   USA 
Reveille et al 
1990 
1975-
1984 
11 12 47 7   USA 
Abu-Shakra et 
al 1995(29) 
1970-
1993 
26 16 32 6.5 4.92 Canada 
Ward et al 
1995(30) 
1969-
1983 
6 34 22 6   USA 
Stahl-
Hallengren et 
al 1999(13) 
1981-
1991 
76 24 6 6   Sweden 
Jacobsen et al 
1999(31) 
1975-
1995 
20 29 20 7 4.6 Denmark 
Moss et al 
2002(25) 
1978-
2000 
17 15 17 20 4.0 United 
Kingdom 
Alamanos et 
al 2003(32) 
1981-
2001 
24 10 10 19 1.5 Greece 
Cervera et al 
2003(33) 
1990-
2000 
19 26.5 25 5.9   Multicenter 
Björnådal et 
al 2004(23) 
1964-
1995 
42 21 1 12 3.63 Sweden 
Bernatsky et 
al 2006(24) 
1958-
2001 
12   5 9 2.4 Multicenter 
Chambers et 
al 2009(20) 
1978-
2004 
20   25 18   United 
Kingdom 
*SMR: standardized mortality ratio. Empty cells = not evaluated 
  
	   15	  
 
Ethiopatogenesis   
The immune system, overview 
The immune system is divided into different lines of defense. The first line is physical 
barriers, like the skin and mucosal membranes.  
The second line of defense is the innate immune system, which comprises the cells and 
mechanisms that defend the host from infection by other organisms in a non-specific 
manner. The innate immune system is fast, but not specific, and does not confer long-
lasting or protective immunity.  The functions of the innate immune system include 
recruiting immune cells to sites of infection, through the production of chemical factors 
called cytokines. By activation of the complement cascade, bacteria are identified and 
opsonized (bound to), and cells (mostly macrophages) are activated to promote 
clearance of dead cells, microorganisms and debris.  Finally, the innate immune system 
also activates the adaptive immune system. 
 
The adaptive, or specific, immune system, is the third line of defense. It is the most 
specialized form of defense, and exists only in vertebrates. It has the ability to recognize 
almost an infinite diversity of specific antigens, through the process of antigen 
presentation. It is also characterized by immunological memory, in which each 
pathogen is “remembered”. The memory cells can be called upon to quickly eliminate a 
pathogen should subsequent reinfections occur. The main cells involved are the B-and 
T- lymphocytes. Clones of these cells have specificity for a certain antigen, and when 
they encounter this antigen, they amplify through clonal expansion, giving an effective 
defense against the invader. The B cells play a major role in the humoral immune 
response, whereas T-cells are intimately involved in cell-mediated immune responses.  
 
The creation of antibodies, the humoral immune response, takes place in B-cells. 
Antibodies are soluble B-cell receptors, which upon encountering their antigen tag it 
and thereby facilitating uptake by macrophages or destruction by the complement 
system.  
 
T-cells constitute the cellular immune response. They recognize an antigen when 
presented to them by dentritic cells, B-cells or macrophages. The T-cells are divided 
into two main subgroups, T-helper (CD4+) cells, and cytotoxic (CD8+) T-cells. The T-
helper cells are further divided into Th1 and Th2 helper cells. The CD8+ cells induce 
death in cells that are infected with microorganisms.  
T helper cells produce large amounts of cytokines, different depending on subtype, with 
the purpose of signaling, recrution, activation, and differentiation of other cells involved 
in the immunological response. Th-1 cells produce interferon-γ (IFN-γ), interleukin 
2(IL-2), interleukin 12(IL-12) and also tumor necrosis factor-α (TNFα), the latter 
although mainly derived from macrophages. Th-1 cells activate macrophages and 
promote a local inflammatory response. IFN-γ primes macrophages and influences B-
cells during class switching to produce IgG3 antibodies, good at opsonizing viruses and 
bacteria and at fixing complement. TNF-α activates macrophages and natural killer cells 
(NK cells), and IL-2 is a growth factor for cytotoxic T-cells and NK cells. Thus, Th-1 
cells intensify the cellular immune system by stimulating the phagocytic effect of 
macrophages, the proliferation of cytotoxic T-cells, and also the production of 
opsonizing antibodies. Th-2 cells secrete interleukin 4, 5 and 10 (IL-4, 5, 10), which are 
important for the humoral immune system. These cytokines activate B-cells, and they  
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promote proliferation into plasma cells, antibody production and Ig class switching .    
 
The complement system 
 
The complement system is made up of a large number of plasma proteins, among which 
the activation of one component activates the next in a cascade reaction. It can be 
activated through three pathways; the classical pathway, the mannose-binding lectin 
(MBL) pathway, and the alternative pathway. The early events of these three pathways 
involve a series of cleavage reactions resulting in the formation of C3 convertase, 
C4bC2a in the classical and C3bBb in the alternative pathway. This leads to cleavage of 
complement component C3 into C3a and C3b. C3b is then involved in a process in 
which the terminal components C5b, C6, C7, C8 and C9 form the membrane attack 
complex (MAC) which can lyse pathogens and certain cells. C3b and other cleavage 
products can also serve as opsonines on bacteria and immune complexes, facilitating 
clearance by macrophages. Other products of the complement system, C5a, C3a and 
C4a, mediate inflammation as they recruit and activate inflammatory cells. The classical 
pathway is mainly initiated by interaction of C1q with antibodies (IgG and IgM) in 
immune complexes and is the main effector of antibody-mediated immunity. The lectin 
pathway is triggered by the binding of MBL (in combination with the protein MASP) to 
certain carbohydrates, for example on bacteria. Finally, the alternative pathway is 
activated without any specific activator by spontaneous hydrolysis of C3 followed by 
interaction with factors B and D. Complement regulatory proteins tightly regulate 
complement activation, preventing both depletion of complement proteins and limiting 
complement-mediated host-cell damage. 
 
The immune system in SLE 
The autoimmune character of SLE suggests that the immune system is reacting against 
self. Multiple immunologic aberrations have been found in lupus, leaving little doubt 
that there is a fundamental derangement of immune homeostasis.     
An overall concept of SLE pathogenesis is impeded clearance of cellular debris and 
apoptotic cells(34, 35), and failure to deplete autoreactive B-cells(36). Accelerated 
apoptosis of circulating lymphocytes and/or impaired clearance of apoptotic bodies may 
increase the amount of nuclear antigens presented to T lymphocytes. This can lead to 
production of autoreactive B-cells and autoantibodies, the latter a cardinal feature of 
SLE. Autoantibodies may induce damage by several mechanisms. Antibodies directed 
against cell surface membranes (e.g. erythrocytes, platelets), eliminate their target 
through complement-mediated lysis or by enhancing phagocytosis by macrophages. 
Another mechanism of antibody mediated tissue injury is deposition of immune 
complexes in tissues. This can be demonstrated by studying the microscopic findings in 
SLE nephritis and cutan lupus erythematosus, where these complexes often are 
abundant. A third possible mechanism for autoantibody mediated damage is by 
antibody dependent cellular cytotoxicity.   
 
It is widely accepted that the activation of the classical complement pathway by 
immune complexes is an important contributor to organ damage in SLE. It can thus 
seem as a paradox that deficiencies within the complement system are strong 
susceptibility factors for development of SLE. However, the physiological activity of 
the early components of the complement pathway, such as opsonization and the removal 
of immune complexes and debris from the circulation, may play a role in host 
protection.  Complement deficiencies/dysfunction, often present in SLE, can be  
	   17	  
demonstrated by the impaired handling of immune complexes and decreased removal of 
apoptotic cells(37). Also, failure to deplete autoreactive B cells probably also involves 
the complement system, as complement is needed for the elimination of self-reactive 
lymphocytes during the maturation of the immune system(38). Furthermore, 
complement are probably also involved in cytokine regulation. It was recently reported 
that C1q can inhibit IFN-α production, suggesting an explanation for the up-regulation 
of the IFN system in SLE(39).    
 
Interferon-α (IFN-α), a type I interferon, is an important cytokine involved in many 
immunological reactions including anti-viral defenses. It has been known for many 
years that patients with SLE have increased levels of IFN-α, and that these levels 
correlate to both disease activity and severity. There is also a correlation between IFN-α 
levels and markers of immune activation in SLE, e.g., anti-dsDNA titers, IL-10, and 
degree of complement activation. Clinically, high levels of IFN-α are associated with 
certain disease manifestations, such as fever, skin rash and leukopenia. The observation 
that IFN-α treated patients with non-autoimmune disorders can develop an SLE like 
syndrome further supports the role of IFN-α in the development of SLE(40, 41).  
Many SLE patients show a pattern of IFN-α-inducible gene expression, the so-called 
”IFN signature”. A type I IFN-signature was recently found in platelets from SLE 
patients, that was highly associated with a history vascular events(42).  
 
Genetics 
SLE has long been appreciated to arise from both genetic and environmental factors. 
Evidence for the genetic contribution for development of the disease come from the 
observation of familial aggregation and increased concordance in monozygotic 
twins(43). The patterns of inheritance are complex, however, and it is generally thought 
that variations in a number of genes are involved, each contributing a small amount to 
the overall genetic risk(44).  
 
The effects from individual genetic risk factors for the development of SLE are 
relatively weak with a few exceptions. In particular, deficiencies in components of the 
classical pathway are associated with SLE(45). C1q deficiency is an extremely rare 
autosomal recessive complement disorder with only around 40 cases reported 
worldwide, associated with a very high risk of SLE or lupus like illness. Over 90% of 
cases develop disease(46). Deficiencies in C1r and C1s, also very rare, are associated 
with SLE in 68% of cases(47). The most frequently occurring homozygous complement 
deficiency in humans is that of complement component 2 (C2), 33% of these 
individuals develop SLE(48). Complete C4 deficiency is extremely rare, whereas 
heterozygous C4 deficiency with C4A or C4B-null alleles is more common. Total C4 
deficiency and the presence of null alleles, especially for C4A, is associated with 
SLE(49). Recently, Yang et al also demonstrated a dose-dependent phenomenon of 
increased SLE risk at low C4 gene copy number. Protection against disease 
susceptibility is observed at high gene copy number(50).  
 
For a long time, the human leukocyte antigen (HLA) system was the only known 
genetic region associated with lupus. The HLA region is located on chromosome 6 and 
contains hundreds of genes, many of which are important in the immune system and in 
autoimmunity. The HLA is divided into three clusters, class I, II and III. Class I 
includes HLA- A, -B and –C, and the classical class I gene products presents antigens to 
CD8+ cytotoxic T cells and are involved in NK mediated cell death. Class II includes  
HLA-DR, -DQ, DP and encodes proteins that present antigens to CD4+ T-helper cells. 
	  18	  
Class III is somewhat different, encoding for immune proteins e.g. complement factors 
and cytokines. 
The HLA region is highly polymorphic and it has been associated with most 
autoimmune, inflammatory and infectious diseases. There is also a high degree of 
linkage disequilibrium across the region, making it difficult to localize the specific 
genetic signal since long stretches of DNA are inherited together as haplotypes of 
alleles. 
HLA class II haplotypes involving the HLA-DRB1 and HLA-DRQ1 loci have been 
described for their association with SLE, and in particular, haplotypes bearing the 
DRB1*1501/DQB1*0602 (DR2) and DRB1*0301/DQB1 (DR3) alleles have been 
associated with increased risk(51, 52). Also, genes within the HLA class III region, 
particularly the TNF-α(53), C2 and C4 gene loci (discussed above) have been in focus 
for research addressing the development of lupus  
 
Although the HLA region to a large extent contributes to the genetic risk of SLE, other 
genes also play a role. For example, Fc receptors for immunoglobulin G, important for 
the clearance of immune complexes, has been implicated as risk genes(54).  Interferon 
regulatory factor (IRF)5(55, 56), ITGAM/ITGAX (57) and PTPN22 (58), also a strong 
genetic risk factor for RA(59), are other genetic risk factors. 
 
STAT4 has reliably been demonstrated to be a strong genetic susceptibility factor for 
SLE(57, 60). STAT 4 transmits signals from the receptors for type I interferon, IL-12 
and IL-23. STAT4 is a latent cytosolic factor that after activation by cytokines, is 
phosphorylated and accumulates in the nucleus. Activated STAT4 stimulates 
transcription of specific genes including IFNγ, a key indicator of T-cell differentiaion 
into Th1 cells(61). STAT4 has also been implicated in the differentiation of Th17 cells, 
a rather new entity of T cells(62). Dependent on IL-23, proinflammatory Th17 cells can 
play an important role in chronic inflammatory disorders(63). The STAT4 risk alleles 
are associated with a more severe SLE phenotype characterised by younger age at 
disease onset, higher frequency of nephritis and presence of anti-dsDNA (64, 65).  
  
Sex hormones 
 
That sex hormones are important for the development of lupus, and for other 
autoimmune diseases, is suggested by the female predominance(66). Hormones may 
have multiple influences on the regulation of the immune system. For example, 
modulation of cell growth and apoptosis, and influence on immunoglobulin production. 
Generally, steroid hormones are implicated in the immune response with estrogenes as 
enhancers at least of the humoral immunity and androgens and progesterone (and 
glucocorticoids) as natural immunosupressants(67). Potential hormonal risk factors 
studied for the development of lupus are age at menarche, oral contraceptives, 
breastfeeding, menopausal status and postmenopausal hormones(68). Treatment with 
dihydroepiandrosterone(DHEA), an androgen, has in some studies been shown to 
reduce disease activity and flares(69). 
Environmental factors 
Cutaneous photosensitivity is a well-known phenomenon in SLE and exposure to 
sunlight has been described as a trigger of SLE flares(70). Dietary constituents are of 
interest as aetiologic risk factors for SLE. Alfaalfa sprouts have been shown to induce 
lupus-like disease(71). Lower levels of vitamin D have been observed in SLE, but it is  
not clear whether this has a causative effect or is a result of the disease(72). Also, 
certain drugs are able to induce a lupus-like syndrome, such as D-penicillamine and 
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sulphasalazine(73, 74). Alcohol might have a protective effect, although the results 
between studies are conflicting(75, 76). Other environmental factors which have a 
potential role in SLE pathogenesis are socioeconomic status, environmental 
contaminants, cosmetics, vaccinations and stress(68). 
  
Smoking 
 
Smoking is a well-established risk factor for the development of rheumatoid arthritis 
(RA). In RA, former, passive and current smokers are at increased risk (Costenbader 
2006). Also, duration and intensity are of importance (Criswell 2002). Smokers seem to 
have a more severe form of RA than non-smokers (Goodson 2004, Stolt P 2003). 
Smoking was first demonstrated to be a risk factor mainly for rheumatoid factor (RF)-
positive RA, and the disease risk was greatly enhanced in individuals carrying certain 
major histocompatibility antigens, more specifically the shared epitope of HLA-DRB1: 
HLA-DRB1 SE(77). Later it has been demonstrated that both smoking and HLA-DRB1 
SE are riskfactors exclusively for anti-citrullinated protein antibody (ACPA) positive 
RA, and that HLA-DRB1 SE is linked to the presence of anti-citrulline immunity(78). 
Evidence for the hypothesis that smoking is able to induce autoantibodies in genetically 
predisposed patients was recently further strengthened by the observation that smoking 
appears to be associated with an increased risk of anti-Jo-1 positivity in HLADRB103-
positive myositis patients(79).   
Current smoking is associated with a small but significant increased risk of SLE. In a 
metaanalysis by Costenbader et al, the odds ratio (OR) was estimated to 1.5 for current 
vs never smokers(80). Data are scarce concerning whether previous smoking or only 
current smoking is a risk factor and whether there is a dose–response relationship 
between smoking and risk for SLE. Some studies indicate that current smokers have 
more serious cutaneous involvement(81, 82) and that there is a relationship between 
smoking and more severe SLE in terms of serositis and renal failure(83, 84).  
Few studies have been concerned with putative mechanisms by which smoking might 
trigger disease. Recently, though, one study was able to demonstrate an association not 
only between smoking and SLE, but also between smoking and occurrence of anti-
dsDNA(85). This finding parallels the relationship between smoking and antibodies in 
RA and myositis. In SLE, however, no study has yet addressed the gene–environment 
interaction between smoking and genes that confer susceptibility to SLE. A study that 
contradicts the results above is the work by Rubin et al(86). They found that anti-
dsDNA IgG were higher in former smokers than current and never smokers. They 
hypothesized that smoking might suppress IgG antibody production, and that after 
smoking cessation, there is an exacerbation of humoral autoimmunity. Also, cigarette 
smoke might also influence the effectiveness of medications; this has been 
demonstrated for hydroxychloroquine(87).  
The effects of smoking on the immune system are complex and not fully understood. It 
may contribute to autoimmunity through several mechanisms. It can cause tissue 
damage and increased apoptosis through generation of free radicals and 
metalloproteinases, induce inflammation, have an immunosuppressive effect and 
finally, it has antiestrogenic effects(88). 
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Figure 1. A possible model for the ethiopatogenesis of SLE 
 
 
Cardiovascular disease 
CVD is the leading cause of mortality in the world. In Europe, CVD accounts for 49% 
of all deaths(89). In Sweden, approximately 40% of all deaths are due to CVD(90) Men 
are affected earlier and more often than women. CVD is rare before the age of 55 in 
women but at menopause there is a steep three to four-fold increased risk of CVD(91). 
Mean age for myocardial infarction in Sweden is 69-70 years for men, and 74-75 years 
for women(92). Although the incidence rates of CVD have been reported to be 
decreasing in the western world, cardiovascular health care is still a large challenge, 
especially in low- and middle-income countries.  
Anatomy and physiology of the artery 
The wall of large arteries consists of three layers, the intima, the media and the 
adventitia. The intima is the innermost layer, and consists of the endothelium, a sub-
endothelial layer of connective tissue and an internal elastic membrane. The media 
consists of smooth muscle cells and collagen fibres. Its principal task is to regulate 
dilatation and constriction of the artery, and to control blood pressure. The adventitia is 
the outer layer consisting of fibroblasts, collagen and elastic fibres. In larger vessels 
there are also nerves, and blood supply (vasa vasorum). The endothelium is the 
continuous monolayer of cells that comes into direct contact with the blood. Its structure 
and functional integrity are important in the maintenance of the vessel wall and 
circulatory function, but the endothelium is by no means inert. As a barrier, the 
endothelium is semipermeable and regulates the transfer of small and large molecules.  
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Endothelial cells are dynamic and have both metabolic and synthetic functions. They 
exert significant autocrine, paracrine and endocrine actions and influence smooth 
muscle cells, platelets and peripheral leucocytes. The endothelium is involved in the 
production of growth factors, matrix products and inflammatory mediators. It has an 
important role in lipid metabolism. It has both antithrombotic and procoagulant 
functions, thereby maintaining blood haemostasis. It is also important in regulating 
vascular tone by secreting vasoactive substances. In this manner, the endothelium has 
emerged as an important mediator in several disease states, including infections, 
hypertension, auto-immune diseases and atherosclerosis(93). 
 
Atherosclerosis- the main cause of CVD 
 
Atherosclerosis is considered to be the main cause of CVD, and it affects all humans to 
a varying degree. Mainly, atherosclerosis is located to elastic and muscular arteries, 
with aorta and its branches, coronary arteries and cerebral arteries being primarily 
affected. The atherosclerotic lesion is located in the intima, between the endothelium 
and the smooth muscle cell layer. The process of atherogenesis begins in early 
childhood with the development of the ”fatty streak”(94). Subsequently, the fatty 
streaks transform into fibromuscular plaques, consisting of a fibro-fatty core 
accumulation covered by a fibromuscular cap. The cap is formed by smooth muscle 
cells from the media, which have infiltrated the intima and have the function of 
surrounding and stabilizing the plaque. The plaque filled with lipids and necrotic debris 
grows slowly, initially it expands outwards with preserved lumen, but finally it causes 
narrowing of the vessel lumen, resulting in ischemia(95). The fibrous cap, initially 
stabilizing the plaque, can eventually become unstable. At this stage the lesion is 
labeled a ”vulnerable plaque” because of the high risk of rupture. If rupture occurs, a 
thrombus is formed, which may lead to total occlusion and a life-threatening 
situation(96). Myocardial infarction, ischemic stroke, sudden cardiac death, chronic 
ischemic heart disease and peripheral arterial disease are among the most common 
manifestations of atherosclerosis.  
Risk factors for atherosclerosis and CVD 
The traditional CVD risk factors (age, male gender, smoking, family history, diabetes 
mellitus, hypertension) are nowadays well established. They are the result of extensive 
epidemiological studies, starting in the city of Framingham in the early 70s, there of the 
name ”Framingham risk factors”(97). Some of them, as smoking, hyperlipidemia and 
hypertension, are modifiable, while others are not. The metabolic syndrome is a 
combination of metabolic CVD risk factors that often occur together, and consists of 
abdominal obesity, high triglycerides and total cholesterol, hypertension, and diabetes 
or insulin resistence (98). This cluster of risk factors is a large and growing problem in 
the industrial world. Although the traditional risk factors account for a substantial part 
of the CVD risk, their prevalence do not seem to fully explain for the cardiovascular 
diseases in the general population. Searching for other risk factors, so called non-
traditional risk factors, has led to the observation of several new biomarkers of 
importance for CVD. Examples of these are C-reactive protein (CRP)(99, 100), 
fibrinogen(101), TNFα(102), cystatin C(100, 103, 104), IL-6(105), von Willebrand 
factor(vWf)(106), vascular cell adhesion molecule-1 (VCAM-1), inter cellular adhesion 
molecule-1 (ICAM-1), E- and P-selectin(107), antiphospholipid antibodies(108, 109) 
and antibodies to oxidized low density lipoprotein (anti-oxLDL)(110, 111). Many of 
these are markers of inflammation or endothelial activation/dysfunction, or 
immunological factors such as autoantibodies and cytokines, suggesting the 
	  22	  
development of CVD to be a chronic inflammatory disease involving the immune 
system.  
Atherosclerosis as a chronic inflammatory disease  
During the last 20 years, atherosclerosis has become recognized as a chronic 
inflammatory disease(112, 113). The most accepted view is the ”response to injury” 
hypothesis, where endothelial injury and the following responses are the initiating and 
driving forces behind the atheropathogenesis.  Activation of the endothelium can be 
induced by risk factors for CVD, such as hyperlipidemia(114), hypertension(115) and 
hyperglycemia(116).  
A major culprit in the initiation of the inflammatory process of atherosclerosis is low-
density-lipoprotein (LDL). The formation of oxidized LDL(oxLDL) plays a significant 
role in the aethiopathogenesis of atherosclerosis(117). OxLDL is formed through 
oxidation of LDL trapped in the subendothelial space during early atherogenesis. 
Hypercholesterolemia leads to infiltration and retention of LDL in the arterial intima, 
initiating an inflammatory response in the arterial wall(118). Modification of LDL 
through oxidation leads to release of phospholipids that can activate endothelial 
cells(119). The activated endothelium expresses different types of leukocyte adhesion 
molecules, that causes circulating blood cells to adhere at the site of activation(120). 
VCAM-1 is upregulated in response to hypercholesterolemia, and the cells having 
counterreceptors for VCAM-1 (monocytes, lymphocytes), adhere to these sites (121). 
Chemokines produced in the intima stimulate the blood cells to migrate into the 
subendothelial space. In the intima, macrophage-colony stimulating factor induces 
monocytes to mature into macrophages. The maturation is associated with up-regulation 
of scavenger receptors and toll like receptors (TLRs). The scavenger receptors 
internalize a broad range of molecules and particles with pathogenic features, there 
among modified LDL(122). This process transforms the macrophage into a foam cell. 
The foam cell grow slowly, unable to degrade its content, ultimately leading to cell 
death and accumulation centrally in the plaque. 
TLRs can, in contrast to scavenger receptors, initiate cell activation(123), and the 
activated macrophages produce inflammatory cytokines, proteases, and cytotoxic 
oxygen and nitrogen radical molecules. Dentritic cells (DCs) that patrol arteries may 
take up LDL components for subsequent antigen presentation in regional lymph nodes. 
In the normal artery wall, resident DCs are thought to promote tolerization to antigens 
by silencing T cells; however, danger signals generated during atherogenesis may 
activate DCs, leading to a switch from tolerance to the activation of adaptive 
immunity(124). 
Endothelial activation also leads to rolling, adhesion and migration of T-cells into the 
site of inflammation. T cells are always present in the atherosclerotic lesion, 
predominately CD4+ cells. The atherosclerotic lesion contains cytokines that promote a 
Th1 response(125), leading to differentiaton of the T cells into Th1 effector cells, 
producing IFN-γ. IFN-γ is a proinflammatory cytokine that augments synthesis of 
TNFα and IL-1(126), further promoting atherosclerosis.  T cell cytokines induce the 
production of many substances downstream in the inflammatory cascade, which can be 
detected in the peripheral circulation, e.g. CRP and IL-6. Subsequently, smooth muscle 
cells (SMCs) in the vessel wall are stimulated to migrate to and proliferate in the intima. 
Moreover, extra-cellular matrix production is stimulated, forming a fibrous cap around 
the cells(112, 127). This process ultimately leads to a thickening of the vessel wall and 
the formation of an atheroma. An advanced atherosclerotic lesion is characterized by a 
core of lipids and necrotic tissue covered by a fibrous cap, comprising SMCs and 
collagen(112). Activated macrophages and SMCs release matrix metalloproteinases 
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(MMPs), degrading the fibrous cap leading to subsequent rupture of the plaque and 
thrombus formation.  
In addition to the proinflammatory process in atherosclerosis, partly due to Th1 cells 
and their cytokines, there are also protective mechanisms. Th2 cells, known to produce 
IL-10, have been associated with protection against atherosclerosis in murine 
models(128). In humans, increased levels of IL-10 have been linked to decreased risk of 
CVD(129). Regulatory T cells (Treg), also producing IL-10, have been implicated in the 
protection against atherosclerosis. Mice transgenic for human apo B, immunized with 
apo B peptide vaccines can be protected from atherosclerosis even in the abscence of an 
antibody response(130). The immunization is associated with an activation of Treg, and 
administration of antibodies directed to Treg blocks the atheroprotective effect of the 
vaccine(131). The importance of atheroprotective antibodies is discussed below.  
 
Involvement of autoantibodies in the development of atherosclerosis 
 
Except for being proinflammatory, oxLDL is also immunogenic, and the immune 
response against oxLDL is considered as a crucial event in atherogenesis(127). 
Neoepitopes on LDL generated through LDL oxidation become targets for auto-
antibodies. Elevated levels of anti-oxLDL have been associated with progression of 
atherosclerosis (110, 132) and cardiovascular disease(110, 111). Although adaptive 
immunity is believed to have a net atherogenic effect, antiatherogenic effects of immune 
responses against oxLDL have also been described. Several experimental studies of 
rabbits and mice where oxLDL has been used for immunization demonstrated a positive 
correlation between high titers of anti-oxLDL and the degree of protection against 
atherosclerosis(133-135). The situation is more complex in humans, as often is the case. 
Different studies show positive or negative correlations, or no correlations, between 
anti-oxLDL titers and atherosclerosis or its features(135-139). Interestingly, titers of 
IgM and IgG antibodies to oxLDL have been found to show differences in their 
associations with coronary artery disease (CAD), suggesting that their biological roles 
differ(140-142). Thus, the repertoire of anti-oxLDL may include both ”protective” and 
”pathogenic” autoantibodies. A possible mechanism for protective antibodies could be 
that under normal circumstances, anti-oxLDL may have a function in clearance of high 
levels of oxLDL. But, upon enhanced LDL oxidation (for example in cigarette smoking 
or inflammatory conditions), autoantibodies with a higher affinity, or targeting different 
epitopes on oxLDL, may be generated, aiding uptake by macrophages and thus 
enhancing foam cell formation and macrophage activation. Also, anti-oxLDL could 
enhance oxLDL uptake by macrophages through involvement of Fc receptors rather 
than scavenger receptors(143). The complexity of anti-oxLDL has been reviewed 
elsewhere(144). Finally, worth mentioning while discussing oxLDL/anti-oxLDL, is 
phosphorylcholine (PC) and its natural antibodies, suggested to possibly influence the 
development of atherosclerosis.  PC is a part of oxLDL, more defined in its structure 
than oxLDL. Recent data suggest that anti-PC antibodies, especially of the IgM 
subclass, could have an atheroprotective effect, as low levels have been associated with 
increased risk of cardiovascular events(145, 146).  The potential role of PC/anti-PC was 
recently reviewed by de Faire and Frostegård(147). 
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 Figure 2.  Inflammation in atherogenesis and atherosclerotic disease progression. 
Adapted from Rhew and Ramsey-Goldman, with permission from the publisher. 
 
 
Cardiovascular disease in SLE 
CVD epidemiology 
That SLE patients are prone to premature cardiovascular disease is nowadays an 
established phenomenon. In 1974, studies by Urowitz et al described the ”bimodal 
pattern” in lupus, where a second mortality peak in the long term outcome of SLE 
patients related to cardiovascular disease was noted(27). In large series of SLE patients 
described since the 1970s, 6-75% of deaths were due to CVD (13, 24, 31, 33, 148, 149). 
Since the 70s, the cardiovascular research in SLE has been growing continuosly, and the 
amount of data is now tremendous. 
Clinical studies 
The premature onset of CVD in lupus is well documented, with the age of first event 
noted on the average to be between 47-51 years(150-152).  The overall prevalence of 
clinical cardiovascular disease varies between 6-10%(150-153). The risk of clinical 
cardiovascular disease in SLE patients varies between studies, but a 2 to 10 fold 
increase compared to the normal population has been reported(154-159). The relative 
risk is especially high among young patients(150, 160), although the absolute risk still 
is higher among older patients. In a classic study by Manzi et al, women with SLE in 
the 35-44 year age group were more that 50 times more likely to have an MI than 
women of similar age in the Framingham study(150).    
Subclinical disease 
Measurements of atherosclerosis are often referred to as subclinical CVD. Autopsy 
studies have demonstrated a prevalence of atherosclerosis in 41-53%(29, 148) of SLE 
patients, regardless of the actual cause of death. Carotid plaques and subclinical 
coronary artery disease have been demonstrated in up to 30-40% of lupus patients(161) 
(162-164) vs 9-16% of controls(161, 164). Most studies on atherosclerosis in lupus are 
cross sectional, but a handful of prospective studies have now also investigated 
progression of atherosclerosis(165, 166), (167-169). Progression also seems to be 
accelerated in SLE compared to control subjects(170).  
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While most studies have demonstrated that the development of atherosclerosis is 
accelerated in SLE, some groups have been unable to confirm these observations (Table 
3). 
 
Table 3. Selection of case-control studies on atherosclerosis prevalence in SLE 
 Surrogate 
measure of 
atheroscleros
is 
No of 
Patients 
No of 
Controls 
Plaques  Intima 
media 
thickness 
Falaschi et 
al 
2000(171) 
Carotid 
ultrasound 
26   26  Not 
measured 
⇑ among 
patients 
Svenungsso
n et al 
2001(172) 
Carotid 
ultrasound 
26 
SLE 
cases 
26 
SLE 
control
s 
26 
control
s 
⇑ among 
SLE cases 
& controls 
vs controls 
⇑ among 
SLE cases 
vs SLE 
controls & 
controls 
Asanuma et 
al 
2003(164) 
EBCT 65 69 ⇑ CAC among patients 
Roman et al 
2003(161) 
Carotid 
ultrasound 
197 197 ⇑ among 
patients 
⇓ among 
patients 
De Souza et 
al 
2005(173) 
Carotid 
ultrasound 
82 62 ⇑ among 
patients 
Not 
measured 
Roman et al 
2005(174) 
Carotid 
ultrasound 
101 105 ⇑ among 
patients 
NS 
Jimenez et 
al 
2005(175) 
Carotid 
ultrasound 
70 40 ⇑ among 
patients 
NS 
De Leeuw 
et al 
2006(176) 
Carotid 
ultrasound 
72 36 NS ⇑ among 
patients 
Lopez et al 
2006(177) 
Carotid 
ultrasound 
30 27 ⇑ among 
patients 
⇑ among 
patients 
Von Feldt et 
al 
2006(178) 
EBCT 152 142 ⇑ CAC among patients 
Chung et al  
2006(179) 
EBCT 93 65 ⇑ CAC among patients 
Kao et al 
2008(180) 
EBCT 157 157 ⇑ CAC 
among 
patients 
Kao et al 
2008 
Rho et al 
2008(181) 
EBCT 109 78 ⇑ CAC 
among 
patients 
Rho et al 
2008 
Colombo et 
al 
2008(182) 
Carotid 
ultrasound 
80 80 ⇑ among 
patients 
⇑ among 
patients 
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Thomson et 
al 
2008(170) 
Carotid 
ultrasound 
217 104 ⇑ among 
patients 
NS 
Huang et al 
2009(167) 
Carotid 
ultrasound 
76 38 Not 
measured 
⇑ among 
patients 
Reynolds et 
al 
2010(183) 
Carotid 
ultrasound 
119 71 ⇑ among 
patients 
⇑ among 
patients 
Gallelli et al 
2010(184) 
Carotid 
ultrasound 
75 75 ⇑ among 
patients 
NS 
McMahon 
et al 
2011(185) 
Carotid 
ultrasound 
250 122 NS NS 
EBCT: electron beam computed tomography 
CAC: coronary artery calcium 
NS: non significant 
 
 
Methods to measure atherosclerosis 
Intima media thickness (IMT) and plaques of extracranial carotid arteries, measured by 
B-mode ultrasound, is the most widely accepted non-invasive marker of subclinical 
atherosclerosis, which has been used in clinical and epidemiological studies to 
investigate the effects of established and non-traditional vascular risk factors(186). In 
addition, in view of its correlation with coronary atherosclerosis (187) and its capacity 
to predict incident coronary events (188, 189), carotid IMT has been proposed as a 
surrogate marker of coronary atherosclerosis(187, 190). Another non-invasive method 
to detect subclinical atherosclerosis is Electron beam computed tomography (EBCT), 
mostly measuring coronary artery calcium (CAC), also predictive of future 
cardiovascular events(191, 192). 
Risk factors for atherosclerosis and CVD in SLE 
Past studies have focused on evaluating risk factors for atherosclerosis, clinical events, 
or both. The results between studies are somewhat diverging, although some features 
are common for all. The traditional risk factors contribute, but cannot totally explain the 
increased risk. Instead, a combination of traditional and lupus-related factors contributes 
to the accelerated and premature atherothrombotic disease in lupus. The increased 
prevalence of atherosclerosis can explain part of the increased risk for CVD in SLE 
patients, but as SLE is a complex disease with the hallmark of immune dysregulation, 
inflammation, endothelial dysfunction and autoantibodies, CVD may also result from 
other mechanisms. Although carotid plaque and IMT are known to predict 
cardiovascular events in the general population(193), prospective studies on 
associations between subclinical atherosclerosis in SLE in relation to clinical events are 
still scarce.    
Traditional risk factors 
Some studies have investigated whether SLE patients have more traditional risk factors 
than controls. Patients with SLE have in some studies been more likely to have 
hypertension, diabetes mellitus, and lipid derangements(158, 194, 195). On the other 
hand, SLE patients have been found to have on average one less classic risk factor at 
time of their event compared to other populations with premature CVD(196). However, 
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after adjusting for traditional cardiovascular risk factors, patients with SLE still have an 
excess risk of CVD(155, 156).     
Even though the traditional risk factors cannot fully explain the increased risk for 
atherosclerosis and CVD in SLE, their role cannot be ignored: 
 
Age: Older age is naturally a strong risk factor for development of both atherosclerosis 
and clinical CVD(162, 197, 198) (164, 199). Many studies so far did not adjust for age 
when evaluating other variables. Given the strong influence by age and the fact that 
many potential CVD risk factors are influenced by age, such as blood pressure(200), 
inflammatory markers(201)and renal function(202), it is difficult to interpret the results 
of these studies.  
Sex: Generally, male sex has been associated with increased risk of CVD (203, 204) and 
atherosclerosis(205, 206).  
Smoking: Smoking is a risk factor for CVD(151), and was the only traditional risk 
factor that prospectively predicted cardiovascular events and mortality in two of our 
studies (paper I,II) and in a study by Toloza et al (198). Smoking is also associated with 
measures of atherosclerosis(205) (207, 208).  
Hypertension: High blood pressure has been demonstrated to be associated with both 
increased risk of cardiovascular events(152, 204, 209, 210) and atherosclerosis(162, 
206). 
Hyperlipidemia: Hypercholesterolemia(150, 152, 211), high very low LDL (VLDL) and 
low high density lipoprotein (HDL)(172) are risk factors for clinical CVD. 
Hyperlipidemia is also associated with atherosclerosis(162). 
Diabetes and overweight: Patients with SLE are more likely than controls to have the 
metabolic syndrome (212), which also is associated with subclinical 
atherosclerosis(199, 206, 213, 214).  Overweight is both a risk factor for CAD(152) and 
atherosclerosis(199). 
In prospective studies of atherosclerosis, mostly traditional risk factors(165, 166) and 
homocystein(168, 169), have been predictive of progression.     
Lupus-related/non-traditional risk factors 
Lipid dysregulation and LDL oxidation 
The typical lipid profile in lupus is characterized by normal total cholesterol value, low 
or normal LDL, high VLDL and TG, and low HDL. This lipid profile is present in 
inactive untreated lupus and is more pronounced in active disease(195). Decreased 
activity of lipoprotein lipase (LPL)(215) or anti-LPL antibodies(216), and antibodies to 
HDL or apo-A1(217) are factors that might contribute to high TG and low HDL, 
respectively. Furthermore, abnormal lipid profiles in lupus have been assocaited with 
increased levels of TNFα(218), monocyte chemotactic protein 1 (MCP-1) and IL-
6(219). The lipid profile in SLE is also affected by medications, such as steroid 
treatment and antimalarias. Steroids lead to an increase in total cholesterol, LDL and 
HDL, but also to some increase of TG levels(220). Antimalarias, on the other hand, 
have an atheroprotective effect on the lipid profile, by increasing HDL and decreasing 
total cholesterol and LDL(221). Renal disease including nephrotic syndrome gives 
elevation of cholesterol, LDL and TG levels(222).    
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Lipoprotein A (Lp(a)) is a lipoprotein subclass which comprises LDL-like particles with 
apolipoprotein a bound to apoB. High levels of Lp(a) is an indepent predictor of 
CVD(223) and have also been reported to be elevated in SLE(172, 224, 225).  
The importance of dysfunctional HDL has been the focus of several recent studies. The 
function of normal, anti-inflammatory HDL is to protect from atherosclerosis through 
transportation of cholesterol out of arterial walls and to prevent LDL from oxidation via 
anti-oxidant enzymes such as paroxonase1 (PON1)(226). In SLE, HDL can loose its 
anti-inflammatory properties, and instead becomes pro-inflammatory (pi-HDL). Pi-
HDL occurs more frequently in SLE patients and is associated with plaque occurence 
and coronary artery disease(227, 228). PON1 is an enzyme with antioxidant activity that 
circulates in plasma attached to HDL.  Its physiological role is to prevent oxidation of 
LDL. Reduced PON-1 activity has been found in SLE compared to controls, and an 
association to CVD has also been suggested(229). Antibodies to HDL have furthermore 
been linked to reduced PON1 activity in lupus patients(230), suggesting that LDL 
oxidation could partly be due to the inhibitory effect from these andibodies on 
PON1(230).   
Enhanced lipid oxidation has been suggested in lupus patients(231). Increased levels of 
anti-oxLDL have been found in up to 50% of SLE patients and have been associated 
with atherosclerosis and CVD(140, 172, 231-234). However, the role of anti-oxLDL in 
lupus related CVD is being debated, as some studies have not been able to confirm 
these associations(235-237).   
 
Antiphospholipid antibodies 
aPL are a heterogeneous group of antibodies, known to be highly thrombogenic. β2 
glycoprotein-1 (β2GP1) is nowadays considered to be the major target of these 
antibodies(238). Antiphospholipid syndrome (APS), which is characterized by aPL in 
combination with thrombotic/obstetric events, are discussed in a section below.  
The association between aPL and thrombosis in SLE is a well established phenomenon 
(239-241). SLE patients with clinical CVD are more likely than those without to have 
positive lupus anticoagulant (LAC)(172, 210, 242). Prospective studies, thereamong our 
own study, have demonstrated an association between aPL and future cardiovascular 
events (159, 198, 243). While the link between aPL and clinical events is established, 
the association between aPL and atherosclerosis in SLE is debated. Some studies report 
associations between aPL and atherosclerosis(208, 244), whereas others have been 
unable to do so(161, 177, 242, 245). 
The first evidence that aPL also could be involved in atherogenesis was provided by 
Vaarala et al, as they suggested that some aPL were able to crossreact with oxLDL in 
lupus(234), thus suggesting a possible link between thrombotic and atherosclerotic 
complications. 
β2GP1 has been shown to bind oxLDL, and the colocalization of the oxLDL/β2GP1 
complex i atheroslcerotic lesions implicate a role in the development of CVD(246, 247). 
One proposed physiological function of β2GP1 is to prevent the uptake of oxLDL via 
scavenger receptors. However, in vitro studies have shown that the simultaneous 
addition of aβ2GP1 may enable the uptake of oxLDL/β2GP1 by Fc-receptors on 
macrophages(248, 249). This could facilitate foam cell formation and represent an 
alternative pathway leading to atherosclerosis. Enhanced levels of oxLDL/β2GP1 
complexes and their respective antibodies have been demonstrated in SLE and in APS 
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patients in comparision to controls(177, 246, 250), and were furthermore associated 
with arterial thrombosis (246, 251). 
 
Endothelial dysfunction and activation 
Growing evidence suggests that endothelial dysfunction serves as a marker of inherent 
atherosclerotic risk. In 1977, Ross et al put forward the response to injury hypothesis, 
which proposes endothelial denudation as the initial stimulus for the development of 
atherosclerotic plaques(252). This hypothesis has evolved to emphasize endothelial 
dysfunction rather than denudation(112), and many risk factors for atherosclerosis such 
as elevated and modified LDL, smoking, hypertension and diabetes have been 
associated with endothelial dysfunction(253). Endothelial dysfunction transforms the 
internal layer of the artery from a non-adhesive, anticoagulant, impermeable barrier to 
one that supports leukocyte diapedesis, is procoagulant and the source of vasoactive 
molecules. 
Endothelial dysfunction and/or damage can be evaluated in different ways. For 
example, it is possible to demonstrate dysfunction by measurements of products 
released from the endothelium such as nitric oxide, prostacyclin, von Willebrand factor 
(vWf) and adhesion molecules. Another method, more functional in its way of 
measuring endothelial reactivity, is flow-mediated dilation (FMD). 
Studies investigating endothelial function through FMD suggest that endothelial 
dysfunction is present in lupus patients naive for vascular events(254-256) although the 
results are discordant(257). A metaanalysis evaluating the utility of FMD as a 
measurement of early vascular involvement was recently published by Mak et al. They 
concluded that endothelial-dependent FMD was impaired in lupus patients versus 
controls, whereas endothelial-independent FMD was not(258) 
Elevated levels of adhesion molecules have been found in SLE patients, and correlate 
with disease activity(259). ICAM-1 are associated with increased coronary artery 
calcification(180, 181), as well as VCAM-1(181), the latter also demonstrated to be 
associated with SLE related CVD(257) and to predict arterial events in SLE 
patients(243). Other endothelial markers/adhesion molecules suggested to play a role in 
lupus related CVD are vascular endothelial growth factor (VEGF)(182), vWf(176, 243) 
and E-selectin(181, 183).  
Another sign of endothelial dysregulation is that SLE patients are found to have high 
levels of circulating apoptotic endothelial cells (260). Endothelial apoptosis contributes 
to loss of endothelial integrity and thereby likely also to the initiation of atherosclerosis 
(261). Apoptotic endothelium is prothrombotic(262), partly because of increased 
expression of phosphatidylserine and loss of anticoagulant properties(263) and also due 
to activation of the TF cascade (260). 
An imbalance between increased apoptosis and improper function of repairing 
mechanisms may aggravate vascular damage. Endothelial progenitor cells (EPC) are 
important contributors to endothelial repair, as they can proliferate and differentiate into 
mature endothelial cells. Decreased levels of EPCs have been implicated in increased 
CVD risk in SLE(264) as well as the general population(265). Type I IFN have been 
suggested to be able to deplete EPCs, supporting the role of IFN in the development of 
SLE related CVD(264). 
Antiendothelial antibodies (aECs) represent a heterogenus group of antibodies 
detectable in various autoimmune conditions(266). Little is still known about the 
antigens recognized by these antibodies. aECs are elevated in SLE, and have been 
suggested to be a disease activity marker in lupus(267). There may be a relationship 
between aPL and aECs, as it has been suggested that aECs may crossreact with oxLDL 
	  30	  
and β2GP1 (268). Furthermore, the binding of aECs to endothelial cells has been 
demonstrated to involve β2GP1(269). aECs may also be able to induce endothelial 
apoptosis(270). Endothelial apoptosis can lead to the exposure of plasma membrane 
phosphatidylserine and subsequent binding of β2GP1(271). This could possibly explain 
some of the association between aECs and aPL, since aPL could be produced after the 
exposure of phosphatidylserine on ECs that are induced to undergo apoptosis by 
aECs(272).   
Inflammatory markers 
Levels of inflammatory markers such as TNF-α(218, 257), MCP-1 and IL-6(219), are 
increased in lupus patients with CVD. CRP is one of the most studied biomarkers with 
respect to cardiovascular risk, and has been demonstrated to predict cardiovascular 
events in the general population(99). In SLE, the results are diverging. In some studies, 
CRP was not associated with prevalent vascular disease(162, 199) nor did it predict 
atherosclerosis(233). However, other studies have suggested CRP to be a predictor of 
vascular events(197, 198) and to be associated with coronary artery calcification 
(CAC)(180). Barnes et al found an association between hsCRP and traditional risk 
factors in SLE and suggested that hsCRP could be of use in the assessment of 
cardiovascular risk, despite the fact that it is not valuable as marker of disease activity 
in SLE(273). Finally, hyperhomocysteinemia has been implicated as a risk factor of 
CVD and atherosclerosis in the general population(274), as well as in SLE(178, 199, 
275).   
Complement and CVD 
End organ damage in lupus is associated with immune complex deposition and 
complement activation in target tissues. Complement activation may also be important 
for the development and progression of atherosclerotic plaques by stimulating 
endothelial cell activation and enhancing recruitment of leucocytes to inflammatory 
sites(276). Immune complexes in lupus can stimulate endothelial cells to express 
VCAM-1, which can promote recruitment of monocytes to the arterial wall(277). The 
anaphylatoxins and chemokines produced by complement activation may also promote 
inflammation and the atherosclerotic process. However, the role of the complement 
system in atherosclerosis development might be dual, as also protective mechansims 
such as removal of apoptotic cells and cell debris from atherosclerotic plaques may be 
of importance(278). 
 
C4d deposition on platelets is rather specific for SLE, and is associated with the 
presence of aPL(279). Sera from patients with aPL have the capacity to activate the 
classical pathway of complement, measured as deposition of C1q and/or C4d on 
platelets. The deposition has been associated with increased incidence of arterial 
thrombosis in SLE patients(280). The mechanism could be that aPL bind to platelets, 
creating immune complexes that are recognized by complement. This might lead to 
increased risk for thrombosis through platelet activation and complement-derived 
inflammatory mediators(280). 
Other potential pathogenetic mechanisms involving complement are C2 deficiency(281) 
and variant alleles of MBL(282) both of which have been associated with CVD in SLE. 
Finally, elevated C3 levels, somewhat counterintuitive, have also been associated with 
CVD risk(170, 207).  
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Disease activity, damage and renal dysfunction 
Disease duration and high SLICC damage-index scores have in many studies been 
demonstrated to be associated with premature CVD in lupus(150, 152, 161, 283). 
Low glomerular filtration rate predicts arterial events in lupus(284). Faurschou et al 
recently demonstrated an disturbingly high cardiovascular risk among young patients 
with lupus nephritis, where the standardized ratio of observed to expected events was as 
high as 42(285). Renal disease and lupus nephritis have also been associated with 
accelerated atherosclerosis(170, 171, 205, 286) and serum creatinine has been identified 
as an independent predictor of IMT progression in SLE(170).  
Cystatin C is a reversible inhibitor of cysteine proteinases that is procuced by most 
cells. It can be used as a marker of glomerular filtration rate (GFR) because it is freely 
filtered at the glomerulus and reabsorbed and catabolized in the proximal renal tubules. 
It is not affected by gender and muscle mass, and it is more sensitive to small decreases 
in renal function. Cystatin C is believed to provide a more accurate measure of renal 
function than creatinine(287). The association between renal impairment and 
atherosclerosis and CVD is well established(288). In recent years, cystatin C has been 
reported as a prognostic marker of cardiovascular disease and death in the general 
population, even after adjustment for renal function measured by standard methods(104, 
289, 290). Several large population studies have also demonstrated an association 
between inflammation and cystatin C(291-293). Thus, cystatin C may serve as an early 
marker for increased CVD risk resulting from suble renal impairment, or perhaps could 
also participate directly in atherogenesis through its role in inflammatory 
processes(294). 
Role of SLE treatment 
Corticosteroids play opposing roles in CVD risk in lupus. Steroids may protect against 
CVD by reducing inflammation and disease activity, but the metabolic effects 
associated with their long-term use implicate increased risk. Accordingly, high doses of 
steroids have been show to increase CVD risk in SLE(199, 210, 214, 220). On the other 
hand, Roman et al demonstrated that lower average prednisone dose and less aggressive 
immunosuppressive therapy such as cyclophosphamide was associated with 
atherosclerosis and carotid plaques in lupus patients(161, 168), indicating that 
aggressive control of disease activity may be important to reduce CVD risk. Also, in the 
context of SLE, steroids are a marker of the severity of the underlying inflammatory 
disease state. As such it is difficult to decide whether to attribute any possible 
association with the drug or the disease phenotype.  
 
Hydroxychloroquine, a commonly used medication in the treatment of SLE, has been 
associated with lower burden of carotid plaques and with protection against CVD in 
lupus(161, 210, 220, 240, 244, 295, 296). The protective effect may be through 
antiinflammatory, antithrombotic(297) and lipid-lowering(298) properties.  
 
Genetic predisposition 
 
STAT4 was recently demonstrated to have a possible interference with cardiovascular 
disease in lupus, when we in paper III showed an association between a STAT4 risk 
allele, stroke and aPL in SLE(299).  
Another genetic finding is that CRP gene polymorphisms have an association with 
arterial vascular events in lupus(300). 
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MBL has also been implicated as a risk factor for CVD. Variant alleles of the gene 
exist, resulting in reduced levels and also a dysfunctional protein(301). Patients with 
low levels of functioning MBL are more prone to infections(301). Studies indicate an 
association between MBL deficiency and susceptibility for SLE(302), and low MBL 
concentrations have been related to the clinical course of SLE, e.g., complicating 
infections(303) and renal involvement(304). However, defects in MBL may also lead to 
increased risk for atherothrombosis. This association has been suggested in the general 
population(305), and in SLE(282, 306, 307), although the results have not always have 
been consistent(308).  
 
                
Figure 4. Premature cardiovascular disease in SLE 
 
Antiphospholipid syndrome  
The antiphospholipid syndrome (APS) is the most common cause of acquired 
hypercoagulability. APS is characterized by one or more thrombotic (venous or arterial) 
episodes or pregnancy morbidity in combination with the laboratory detection of 
antiphospholipid antibodies, aPL(309).  
Ethiopathogenesis 
The lupus anticoagulant (LAC) was a phenomenon discovered first in lupus patients, 
thereof the name. Later on, it was demonstrated that antibodies responsible for LAC 
activity in vitro recognize phospholipids(310). The name lupus anticoagulant is a 
misnomer, as LAC is not specific for lupus patients, and anticoagulant only in vitro. In 
vivo, a positive LAC test is strongly associated with enhanced risk of thrombosis.  
The broad range of aPL is now known to include antibodies against anionic 
phospholipids (such as cardiolipin, phosphotidyethanolamine, phosphatidylserine, 
phosphatidylglycerol, phosphatidylinositol), their putative protein cofactors such as 
β2GP1(238, 311), prothrombin, protein C, annexin V, or a complex between 
phospholipid and protein(312). 
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At present, the antibodies used in clinical practice for the diagnosis of APS are LAC, 
aCL IgG and IgM, and aβ2GP1 IgG and IgM(309). The major antigenic target of this 
heterogeneous group of antibodies is the plasma protein β2GP1(238). LAC reactivity is 
thought to be mediated mainly by antibodies against β2GP1 and prothrombin(313, 314).   
The etiology and pathogenesis of APS is complex and multifactorial. Normal 
individuals occasionally have elevated levels of aPL(315), and as with other 
autoantibodies, the prevalence increase with age, especially among elderly patients with 
coexistent chronic diseases(316).  
The development of APS is under the control of both genetic and environmental factors. 
Clinical manifestations of APS only occur in some patients with aPL(316). The fact that 
some patients have aPL for years and only develop clinical events under certain 
conditions has given rise to the theory that a “second hit” is sometimes required to 
trigger APS. Various factors might influence the development of events, such as 
specificity and titers of aPL, immobilisation, surgery, trauma, drugs and 
pregnancy(317). A well known environmental trigger for aPL are infections, both viral 
and bacterial. For example, Cytomegalovirus, Epstein-Barr virus, Parvovirus B19 and 
Mycoplasma pneumoniae have been associated with aPL, but also the clinical 
events(317). Supporting the influence by environmental factors on aPL production is 
the finding of aPL in spouses of SLE patients(318).  
APS can be ”primary”, as the only feature, or ”secondary”, if associated with SLE or 
other non-lupus disease. Among SLE patients, 30-50% have aPL, and about a third of 
these develop secondary APS(316). 
 
How these antibodies actually lead to thrombosis is still not known. A lead is that all of 
the tests used in clinical practice for diagnosing APS (aCL, LAC, aβ2GP1) need β2GP1 
for their optimal performance(309). Thus, β2GP1 has an important but unknown role in 
the pathogenesis of APS. The physiological function of β2GP1 is not totally known. It is 
thought that, after a conformational change of the protein (that occurs upon binding to 
anionic surfaces), new epitopes are exposed. The antibodies directed against the protein 
can then bind and stabilize it, inducing a new function(319).    
Many theories have been proposed for how aPL induces thrombosis and foetal loss, but 
none of them have been proven with convincing evidence. Among the most popular 
hypotheses are activation of different cell types (endothelial cells, monocytes, platelets, 
neutrophils), inhibition of protein C, increased thrombin generation, complement 
disturbances and altered fibrinolysis(320). Ways by which aPL could promote 
development of atherosclerosis have been discussed earlier. For example, aCL can 
induce monocyte adherence to endothelial cells through upregulation of adhesion 
molecules(321), oxLDL/β2GP1 complexes are localized in atherosclerotic plaques(246), 
and anti-β2GP1 may accelerate the uptake of oxLDL by macrophages(248). 
 
Clinical manifestations 
 
Venous thromboembolic events are the most common initial clinical findings in APS, 
and are generally also more common than arterial events(322). The site of the first event 
(arterial or venous) tend to predict the site of subsequent events(323), although some 
patients present cumulatively with both arterial and venous events. 
As already mentioned, in SLE, the association between aPL and CVD has been 
demonstrated repeatedly. This is also true for the general population. Patients with 
coronary artery disease have higher levels of aPL than healthy controls(109) and aCL 
antibodies(324), particularly aβ2GP1, are risk factors for myocardial infarction(108, 
325-327). The association between aPL and CVD is especially strong with respect to 
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cerebrovascular disease, and the highest risk is associated with a positive LAC test (328, 
329). LAC is furthermore established as the strongest risk factor among the aCL for 
thrombosis, irrespective of the site and type of thrombosis(330). 
APS and atherosclerosis 
The detection of atherosclerosis in primary APS has lagged behind that in SLE for the 
lack of suitable large study populations. There are however some studies that have 
focused on whether atherosclerosis is increased in this patient group. Although there is a 
theoretical background for the involvement of aPL in the pathophysiology of 
atherosclerosis, the results on atherosclerosis in APS through measuring carotid plaques 
or IMT are diverging.                      
Some studies demonstrated increased subclinical atherosclerosis in primary(331-336) or 
secondary (337) APS patients in comparision with controls, while others have not been 
able to confirm this association(175, 338).   
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Patients and Methods 
Patients and study design (I-IV) 
All patients at the Department of Rheumatology, Karolinska University Hospital Solna, 
who fulfilled four or more of the 1982 revised American College of Rheumatology 
Criteria for classification of SLE(6) were asked to participate. 208 agreed and were 
included in the cohort during the period July 1995-December 1999. The initial 
investigation included an interview and a physical examination by a rheumatologist and 
blood samples were collected after overnight fasting. This cohort is the basis for paper I 
and II. In paper I, 182 of the 208 patients were free of previous arterial events and were 
included. Mean time of followup was 8.3±1.2 years in paper I, and 12.3±3.3 years in 
paper II.            
In 2004, reinclusion of patients began, and continued until 2010. Surviving patients 
from the original cohort, as well as new patients diagnosed since 1999, were asked to 
participate. This cohort is the basis for paper III and IV. In paper III, in addition to 
patients from the Karolinska cohort (N=293), patients from Uppsala(N=131), and Lund 
(N=154) were included. If patients were related only the first case in each family was 
included; thus the study population included unrelated patients. Matched controls were 
genotyped to give a comparison to the local genetic background (N=651). In paper IV, 
367 patients were included. Paper I and II have a prospective design, whereas III and IV 
are cross-sectional. 
The studies were approved by the local Ethics Committee of the Karolinska Hospital, 
Stockholm, Sweden. All subjects gave their informed consent before entering the 
studies. 
 
 
Figure 4. Studydesign 
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Disease activity and damage (I, II, IV) 
SLE disease activity was determined with SLAM(9) and organ damage with the 
SLICC/ACR damage index(153). A SLAM score>6 was considered active 
disease(339). These were done at the initial inclusion for all patients. 
Definition of vascular events (I,III,IV) and determination of causes of mortality(II) 
Vascular events were defined as:  
1) Ischaemic heart disease (IHD): myocardial infarction (MI, confirmed by 
electrocardiography and a rise in plasma creatine kinase, muscle and brain fraction 
(CKMB) or troponin T) or angina pectoris (confirmed by exercise stress test).  
2) Ischaemic cerebrovascular disease (ICVD): cerebral infarction (confirmed by 
computer tomography) or transitory ischemic attack (TIA, defined as transient focal 
symptoms from the brain or retina with a maximum duration of 24 hours).  
3) Ischaemic peripheral vascular disease (IPVD): intermittent claudication or peripheral 
arterial thrombosis/embolus (confirmed by angiogram or Doppler flow studies).  
4) Death due to ischaemic vascular disease: death due to myocardial infarction, heart 
failure, sudden death, cerebral infarction, generalized atherosclerosis as stated by death 
certificate.  
5) Venous thromboembolism (VTE): defined as deep vein thrombosis, confirmed by 
venography or ultrasonography and/or pulmonary embolism, confirmed by radionuclide 
lung scanning or angiogram. 
 
Any arterial event (in paper III, IV)= any of 1-3 
1-3,5: used in paper III, IV 
1-4: used in paper I 
4: used in paper II 
 
In paper II, survival status was followed up in the national population registries through 
March 26, 2010. Death certificates were collected from the Cause of Death Register of 
The National Board of Health and Welfare. When available, autopsy protocols were 
collected from the Department of Pathology Karolinska University Hospital, and from 
the Department of Forensic Medicine.   
Genotyping (III) 
The SNP rs10181656 had previously been genotyped using the GoldenGate assay 
(Illumina inc.) and the SNPstream system (Beckman-Coulter inc.) in two Swedish SLE 
cohorts from Mid and Southern Sweden. These two cohorts comprised 424 and 154 
patients respectively. From Mid Sweden 457 controls were included, and from Southern 
Sweden 194 controls were available. 
 
Laboratory measures (I, II) 
High sensitivity C-reactive protein (CRP), α-1 antitrypsin, fibrinogen and Serum 
Amyloid A (SAA) were measured using BN ProSpec System (Dade Behring). C3 and 
C4 were analyzed using IMMAGETM and C3d using an ARRAYTM system (both 
instruments from Beckman Coulter). Albumin, apolipoprotein A1, apolipoprotein B, 
homocysteine and Cystatin C were measured on an Architect Ci8200 analyzer (Abbott 
Laboratories). Creatinine, HDL-, LDL-and total cholesterol, triglycerides and urea were 
analyzed on LX20 chemistry analyzer (Beckman Coulter).   
Enzyme-linked immunosorbent assays (ELISA) were used to measure soluble Vascular 
cell adhesion molecule (sVCAM-1), von Willbrand factor (vWF, antisera from Dako) 
	   37	  
calibrated against Liatest (Diagnostica Stago) and IL-6 (high sensitivity ELISA, R+D 
systems). Intra-assay coefficient of variations for the ELISAs were <7%. Plasma 
electrophoresis was analyzed on agarose gels.    
 
Autoantibodies(I-IV) 
In paper I and II, ANA were analyzed by immunofluorescence on HEp-2 cells 
(Immunoconcepts, Sacramento, CA, USA) and auto-antibodies to SSA, SSB, Sm and 
RNP using ANA-profile ELISA (PharmaciaDiagnostics), Innolia Immunoblot 
(Innogenetics), and Immunodiffusion (Immunoconcepts). Anti-doublestranded DNA 
(dsDNA) antibodies were determined by Crithidia lucillae kinetoplast assay 
(Immunoconcepts). Anticardiolipin antibodies (aCL) were measured by ELISA using 
ethanol fixed cardiolipin (Sigma-Aldrich) and HRP-conjugated rabbit anti-human IgG 
and IgM (Dako). Positivity was calibrated against Harris standard (Louisville). aβ2GP1 
IgG were analyzed by ELISA (Orgentec).  
In paper III and IV, aCLIgG/IgM and aβ2GP1 IgG were analyzed by ELISA (Orgentec, 
Mainz, Germany). Anti-prothrombin (aPT, IgG) were analyzed by ELISA 
(Orgentec)(paper II). Lupus anticoagulant (LAC) was determined using a modified 
Dilute Russel Viper Venom method, (Biopool) using Bioclot LAC (I-IV). 
 
Statistics(I-IV) 
Characteristics of the study populations were described first using descriptive statistics 
such as medians and interquartile range or mean ± SD for continuous variables, and as 
percentages for categorical variables. For continuous variables, comparisons were made 
by ANOVA/t-tests, Mann-Whitney U-test or Kruskal-Wallis test as needed. Chi-square 
and Fischer´s exact test were used to evaluate categorical variables as appropriate.  
Papers I and II: Univariate and multivariable-adjusted Cox proportional hazards 
regression models were used to evaluate a number of baseline variables as risk factors 
for the first CVE (I) and mortality (II). Because of limited number of first CVEs and 
deaths, we restricted the amount of variables in the multivariable models to four.   
In paper I, baseline variables were sorted into functional groups. After adjusting for age, 
the variables from each group that were representative and most significantly associated 
(i.e. had the smallest p-value) with future CVEs were included in a multivariable-
adjusted model. 
In paper II, the two predictors most strongly associated with mortality after age-
adjustment (in terms of p-value) were retained in all multivariable analyses. Thereafter 
each baseline variable was considered separately, i.e. included one by one in a 
multivariable model containing age and the two other predictors. Furthermore, models 
were stratified by sex, steroid treatment, and nephritis to investigate possible effect 
modification by these factors. The SMR was calculated using age-, sex- and calendar 
year specific mortality rates for the Swedish population. SCORE was calculated using 
Swedish heart score (www.heartscore.org). 
Paper III:  Fischer´s exact test was used to test for Hardy-Weinberg equilibrium of 
genotypes. OR and 95% CI were calculated from 2x2 contingency tables and Mantel-
Haenszel estimates were used for summary measures of the two investigated patient 
groups from mid and southern Sweden. Univariate and multivariable-adjusted logistic 
regression analyses estimated the impact of risk factors on ICVD and IHD events.  
	  38	  
Paper IV: Multivariable-adjusted logistic regression models estimated the association 
between smoking and aPL status. Smoking was defined as never, former, current and 
ever (=former+current). Never smoking was used as reference in all calculations. 
Stratifications for various variables (sex, warfarin treatment, previous arterial/venous 
events, and by exclusion of patients who stopped smoking after event) were made to 
evaluate effect modification and possible reverse causation.  
All statistical analyzes were performed using JMP software (SAS institute, North 
Carolina, USA), with the exception of SMR, where SAS 9.2 was used. A p-value ≤0.05 
was considered statistically significant.  
  
Results 
Paper I 
Predictors for the first cardiovascular event in patients with systemic lupus 
erythematosus – a prospective cohort study 
Patients with SLE have increased risk for cardiovascular disease. Few studies have 
evaluated risk factors for cardiovascular events (CVE) prospectively. Therefore, we 
investigated traditional and lupus-associated risk factors for the first ever CVE 
longitudinally in a cohort of 208 patients. 26 patients had a previous event and were 
excluded. 
Results 
182 patients were included and followed up after an average of 8 years during which 
time13% (24 patients) had a first CVE. When evaluating the traditional risk factors in 
age-adjusted Cox regressions only current smoking was associated with CVE. sVCAM-
1, vWf, low plasma albumin, fibrinogen and aPL, predicted CVEs. aSSB was inversely 
associated with CVE. Of SLE manifestations, arthritis, pleuritis, previous venous 
occlusion and absence of thrombocytopenia predicted events. In a multivariable Cox 
regression model restricted to four variables age, any positive aPL, vWf and absence of 
thrombocytopenia remained as predictors for the first CVE. 
 
Conclusions 
We identified cigarette smoking as the most important traditional CV risk factor, and 
demonstrated that aPL, high levels of endothelial markers (sVCAM-1 and vWf) and 
absence of thrombocytopenia were associated with the first CVE. This indicates that 
endothelial activation and damage, as well as coagulation dysregulation are important 
for CVD in lupus patients. Furthermore, the risk of CVEs seems to differ between 
subgroups of patients, where patients with manifestations such as arthritis and serositis, 
often associated with more systemic inflammation, may be at a higher risk than patients 
with more mild disease represented by for example photosensitivity and aSSA/SSB. 
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Paper II 
Risk factors for cardiovascular mortality in patients with systemic lupus 
erythematosus- a prospective cohort study 
The prognosis for patients with SLE has improved over the years. As patients with SLE 
live longer, cardiovascular disease has become more evident as a cause of morbidity 
and mortality. While death due to infections and active disease has decreased, CVM 
shows no such decline. There are a lot of studies examining risk factors for overall 
mortality in SLE, but few have specifically investigated risk factors for CVM in lupus. 
In this study, we prospectively examined a set of potential risk factors and the European 
heart SCORE in a SLE cohort of 208 patients. We determined causes of death and 
investigated baseline markers for all-cause mortality and specifically for CVM.   
Results 
After a mean follow-up time of 12 years, 42 of 208 patients died. The SMR was 2.4. 
Almost 50% of deaths were classified as CVM. SCORE underestimated CVM in this 
population, but not significantly. Several baseline parameters differed between deceased 
and surviving patients and persisted after adjustment for age. Age, high levels of 
cystatin C and established arterial disease were the strongest risk factors for all-cause 
mortality and CVM. In multivariable-adjusted Cox regression, after adjusting for these 
variables, only smoking from the traditional risk factors predicted CVM. sVCAM-1, 
hsCRP and warfarin treatment also remained significant. Stratification for sex, steroid 
treatment and nephritis did not change the results. 
Conclusion 
Cardiovascular disease was the main cause of mortality in this study. Age and 
established arterial disease were, as expected, strong risk factors for mortality. Except 
for smoking, traditional risk factors did not predict CVM. Instead, high levels of 
cystatin C, inflammatory and endothelial markers differ between patients with a more 
favourable vs. poor prognosis. 
Paper III 
A STAT4 risk allele is associated with ischaemic stroke and phospholipid antibodies 
in systemic lupus erythematosus 
While overall prognosis in SLE has improved, vascular mortality seems to remain 
constant. Nontraditional risk factors such as inflammatory markers and antiphospholipid 
antibodies contribute to this increased risk. Also, genetic predisposition has been 
demonstrated to be associated with risk of CVD. After the MHC region, STAT4 is one 
of the strongest susceptibility factors in SLE. We investigated a possible association 
between the previously replicated SLE risk genotype in STAT4  (SNP rs10181656) and 
vascular manifestations and aPL in SLE. 
Results 
578 patients and 651 controls were available for analysis. The STAT4 risk allele was 
more common among SLE patients with a history of arterial events, more specifically 
those who had experienced ICVD. There was a dose-dependent relationship between 
previous ICVD and number of risk alleles, where homozygous patients had the highest 
for ICVD. STAT4 was also associated with occurrence of more than two aPL, and there 
was a dose-dependent relationship between the number of STAT4 alleles and percentage 
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of patients with ≥ 2 aPL. Adjustment for available known risk factors did not attenuate 
the association between STAT4 and ICVD. Positive aCLIgG also remained as an 
independent risk factor for ICVD.  
Conclusions 
Patients with the STAT4 risk allele have increased risk of ICVD. STAT4 is also 
associated with prothrombotic aPL. Genetic predisposition is an important risk factor 
for ICVD in SLE patients, and aPL may be one underlying mechanism.  
Paper IV 
Cigarette smoking and antiphospholipid antibodies in systemic lupus erythematosus 
Smoking is a known environmental risk factor for development of autoimmune disease, 
for example in RA and SLE. In RA it has been suggested that patients with a certain 
genetic predisposition (the ”shared epitope”) have a higher risk of developing RA, and 
more specifically, ACPA-positive RA. In SLE, smoking has been associated with the 
presence of anti-dsDNA, suggesting that smoking may trigger autoantibodies. aPL are 
often present in SLE patients, and is an established risk factor for thrombosis. As 
smoking is known to induce autoantibodies, and both smoking and aPL are associated 
with cardiovascular disease, we investigated a possible association between the two in a 
cohort of 367 lupus patients.   
Results 
aPL seropositivity varied with smoking status. When comparing ever vs. never smokers, 
ever smokers were more likely to be positive for aCL IgG, aβ2GP1 and LAC. When 
splitting ever smokers into former and current, former smokers were most likely to be 
aPL positive, followed by current and never smokers. In multivariable analyses, 
adjusting for age, sex, and age at diagnosis, the association between former smoking and 
occurrence of aCLIgG, aβ2GP1 and LAC remained. Sex stratification did not change the 
results. In the warfarin free patients former smoking and aPL were no longer 
significantly associated. Also, in the stratum of patients who did not have history of 
events, there was no association between smoking and aPL. However, when excluding 
patients who stopped smoking after event, the association remained. 
Conclusion 
Smoking was associated with the occurrence of aPL. Specifically, former smoking had 
the strongest impact on aPL positivity. The possibility of reverse causation (i e that aPL 
positive smokers who experienced an event were more likely to stop smoking, and 
therefore be classified as former smokers, thus the association) cannot be definitely 
excluded. It will be investigated in forthcoming studies. 
  
	   41	  
General Discussion and future perspectives 
This thesis has focused on investigating risk factors for cardiovascular disease in SLE, 
the main cause of long-term morbidity and mortality among these patients. Traditional 
risk factors, lupus related risk factors, systemic inflammation, endothelial dysfunction, 
autoantibodies and genetic aspects have been in focus. The findings are very interesting 
and shed light on some potential pathogenic mechanisms for cardiovascular disease in 
SLE. 
Causes of death 
In paper II, we investigate causes of death and risk factors especially for cardiovascular 
mortality in lupus. The estimated SMR of 2.4 is consistent with other recent studies(24), 
as well as the observed survival rate of 80% after 12 years(13, 32, 340). In our study, 
cardiovascular death accounted for nearly 50% of deaths, the percentage in other studies 
vary but generally, CVM account for a substantial part in most recent studies(13, 24, 
31). We used the same strategy as most previous studies to determine causes of death, 
i.e. we relied predominately on death certificates, autopsy reports and medical 
charts(31). Some studies also used information from the family(17) and from 
discussions with the patients doctor(25, 33). Two other large studies on the other 
hand(23, 24), one of which is a multicenter study(24), used ICD-codes (international 
classification of diseases) to determine causes of death, the same method as the Cause 
of Death Registers use. National mortality data is based only on the ICD-codes derived 
from the death certificate, and refers to the specified underlying cause of death. As we 
used additional information to determine cause of death, the results may differ. It is 
therefore also difficult to compare the results from different studies and it is not possible 
to calculate cause-specific SMRs. Generally, the results from studies on mortality in 
lupus do not always support each other in respect to causes of death and risk factors. 
The differences may result from the above described methodological variations, patient 
selection and ethnicity, follow-up, definition of study variables, statistical analyzes and 
other confounding factors.  
Cystatin C 
Cystatin C emerged as a novel and strong predictor for CVM and all cause mortality 
paper II. A plausible link between increased cystatin C and impaired cardiovascular 
outcome is reduced renal function. However, in our study, other measures of renal 
function did not predict cardiovascular mortality, and other studies have also 
demonstrated that cystatin C is an independent predictor of poor prognosis, regardless 
of renal function(290, 341). It is possible though, that the prognostic value of cystatin C 
is due to its ability to detect preclinical renal dysfunction, not caught by ordinary 
measurements of GFR. In most studies, creatinine based formulas were used, not direct 
measurements of GFR, hence, it’s difficult to determine the extent to which cystatin C 
concentration reflects kidney function. Inflammation, associated with atherogenic 
changes, may be another mechanism linking cystatin C to cardiovascular risk. High 
cystatin C levels correlated with high levels of CRP(291). Although it is possible that 
this association also could be the result of the presence of renal dysfunction(291, 292, 
342), it has been suggested that high cystatin C levels are directly related to both 
inflammation and atherosclerosis(343). The cystatin C gene is one of the so-called 
”house-keeping genes”. Cystatin C is an inhibitor of lysosomal and cysteine proteinases 
and it is produced in almost all nucleated cells at a stable rate. There is evidence that an 
imbalance between elastolytic enzymes and their inhibitors, cystatin C being one, are 
involved in the pathogenesis of atherosclerosis(344, 345). The increased levels of 
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cystatin C may reflect an attempt to counterbalance a potentially damaging increased 
elastocytic activity stimulated by inflammatory cytokines, the latter also associated with 
atherosclerosis(344). A recent study by Lertnawapan et al found that cystatin C levels 
(but not other measures of renal function) were higher in lupus patients than controls, 
and that they were associated with systemic inflammation, but not with 
atherosclerosis(346). Also in RA, levels of cystatin C have been shown to correlate with 
disease activity, in contrast to other measures of renal function(347). Further research is 
required to gain insight into the true significance of increased cystatin C concentrations 
in these various clinical settings.  
Inflammation and endothelial activation 
In paper I and II, the importance of inflammatory markers as predictors for 
cardiovascular outcome, such as fibrinogen and hsCRP, was demonstrated. 
Inflammatory markers have repeatedly been shown to be important risk factors for 
cardiovascular morbidity and mortality in the general population(99, 348, 349). Also in 
SLE, the relationship between inflammatory markers and cardiovascular outcomes have 
been investigated, although prospective studies are more scarce(172, 180, 198) but the 
impact on mortality has not previously been well studied.  
What was seen for inflammatory markers can also be applied for markers of endothelial 
activation/dysfunction. sVCAM-1 was in papers I and II, and wWf in paper I, strongly 
associated with cardiovascular outcomes. When the endothelium is activated, as in 
inflammatory conditions, these biomarkers are upregulated. sVCAM-1 is an adhesion 
molecule, enhancing adhesion and rolling of leukocytes and subsequent migration into 
the subendothelial space, thereby enhacing the inflammatory and atherosclerotic 
process(350). It has been shown that sVCAM-1 is associated with increased risk for 
clinical CVD and atherosclerosis in the general population(351). In lupus, sVCAM-1 
has been linked to active disease(259), nephritis(352), atherosclerosis(176, 181) and 
manifest CVD(257). However, in the context of SLE mortality, endothelial markers 
have not previously been investigated. Increased plasma levels of vWf are present in 
acute coronary syndromes and has pro-thrombotic effects as it promotes aggregation of 
platelets(106). In lupus, high levels of vWf could be attributable to pro-inflammatory 
cytokines and autoantibodies, both demonstrated to be able to cause release of vWf 
from endothelial cells(106, 353). Previous studies have suggested the importance of 
endothelial activation and dysfunction in lupus related cardiovascular disease, and we 
extend these findings by showing that increased levels of endothelial markers are strong 
predictors of both cardiovascular events and mortality 
Antiphospholipid antibodies 
Another important risk factor for the development of thrombosis are aPL. In papers I, 
III and IV, the significance of these autoantibodies in cardiovascular morbidity and 
potential pathogenesis is suggested. In paper I, aPL predicted the first arterial event, and 
in paper III aPL were associated with ICVD. aPL are well established risk factors for 
cardiovascular morbidity, both in the general population and in lupus(240, 241, 325, 
326, 329). However, in paper IV, aPL did not influence the risk of CVM. This might be 
explained by the fact that aPL seem primarily to be a risk factor for ICVD rather than 
IHD(299, 322, 328, 329), and only one patient died from ICVD. In paper III, the STAT4 
risk allele was associated with aPL, thereby suggesting a possible pathogenic 
mechanism by which the susceptibility gene may predispose for ischemic events. In 
agreement with these results, STAT4 has also been shown to be associated with 
APS(354). However, other studies examining the link between STAT4 and CVD in RA 
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and patients with chronic kidney disease did not find any apparent associations(355, 
356). Other mechanisms by which STAT4 could promote cardiovascular events are 
through inducing a pro-inflammatory behavior in endothelial cells(357) or proliferation 
of vascular smooth muscle cells(358). Promotion of differentiation of T helper cells into 
Th1 cells could be another mechanism, believed to be of importance for the 
development of atherosclerosis, as previosly discussed(124). 
Smoking 
The importance of smoking, one of the most established traditional risk factors for 
CVD, was demonstrated in papers I, II and IV. In papers I and II, smoking was the only 
traditional risk factor that predicted cardiovascular outcome in multivariable-adjusted 
analyzes. The importance of smoking for the development of CVD is established and 
needs no further description. The relative contribution of smoking to the development 
of cardiovascular disease in lupus differs between studies, but some have found an 
association both with subclinical atherosclerosis and clinical CVD(198, 207). Smoking 
has detrimental effects on the immune system(359), and it has been shown to increase 
the risk for both RA and SLE(80, 360). In RA, smoking is important for the 
development of ACPA positivity, especially in patients with the genetic predisposition 
referred to as the ”shared epitope”(360). In lupus, smoking has been shown to be 
associated with anti-dsDNA, suggesting pathogenic mechanisms (85). In paper IV, a 
strong association between former smoking and aPL was found. The reason for this 
association could be that smoking induces the production of aPL, as was also suggested 
for anti-dsDNA. The pathogenic mechanisms behind such an induction remains to be 
determined. Another plausible explanation for the observed between former smoking 
and aPL could be ”reverse causation”, described in the discussion in paper IV. 
Nevertheless, our observation is important. Patients who had a history of smoking and 
had aPL were at much greater risk of having a history of venous/arterial events 
compared to those who had either risk factor (ongoing analyses). Thus smoking may be 
considered as another type of ”second hit” leading to thrombotic events in aPL positive 
patients. Infections, trauma, pregnancy has previously been suggested to constitute such 
“second hits” in patients with aPL/APS(317) and in the catastrophic APS(361). Taken 
together, our results demonstrate that aPL are very important risk factors for 
cardiovascular morbidity in lupus, that genetic factors influence the occurrence of aPL, 
and that smoking history is associated with these autoantibodies. 
Disease activity and lupus phenotype 
SLE patients with more severe disease, represented by high scores on activity- and 
damage indices clearly have worse prognosis(20, 362, 363). Patients with higher disease 
activity and damage also have higher risk of cardiovascular disease(241, 364, 365). As 
cardiovascular disease is included as an item in the SLICC damage index, it can 
sometimes be difficult to determine cause and effect determined by this damage index. 
The finding in paper I that absence of thrombocytopenia was a risk factor for the first 
CVE was unexpected and not consistent with previous studies. Thrombocytopenia, a 
usual finding SLE patients, is usually associated with active disease(366, 367), and has 
been associated with mortality in several studies(366, 367).  Why we found an inverse 
association is difficult to explain. Theoretically, thrombocytopenia may, as a “natural 
anticoagulant”, protect against thrombotic events, but this hypothesis has to be tested in 
larger samples.   
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In paper I, patients with arthritis and serositis, often representing patients with more 
systemic inflammation, had a higher risk of CVE. In both paper I and II, aSSA and/or 
aSSB positivity was inversely associated with cardiovascular outcomes. In paper II, 
anti-dsDNA and neurological manifestations were risk factors for mortality. In clinical 
practice, patients who have aSSA/-SSB often have a milder clinical course with 
muskuloskeletal problems and skin manifestations, while anti-dsDNA positive patients 
more often have tendency to develop nephritis, serositis and other more serious 
manifestations. Our observations are in agreement with others, where aSSA and 
photosensitivity have been inversely linked to mortality (19, 368), while renal 
impairment as measured by estimated GFR, was a risk factor for CVD(369). Thus 
differences in autoantibody profile and clinical course represent different lupus 
phenotypes, and are likely partly due to genetic differences. Further studies are ongoing 
to delineate the different SLE phenotypes. 
Thoughts for consideration 
Many studies use the terms “atherosclerosis” and “cardiovascular disease” as if they 
were interchangeable. Of course, atherosclerosis is a risk factor for the development of 
cardiovascular disease (i e clinical events; coronary artery disease, ischaemic 
cerebrovascular disease and peripheral vascular disease), at least in the general 
population, but it should not be forgotten that there are individuals with advanced 
atherosclerosis who never develop CVE. Prospective studies on the association between 
atherosclerosis and clinical CVD in lupus are still very scarce. To our knowledge, there 
has only been one abstract on this topic, still not published, presented at ACR in 
2008(370).                    
Furthermore, studies investigating risk factors for CVD vary with respect to definition 
of outcome. Some studies only focus on coronary artery disease, others on the 
combination of IHD, ICVD and IPVD, and still others combine arterial and venous 
events. It is therefore difficult to compare studies, as risk factors for the different 
vascular manifestations may be different.  
Finally, vascular events may result from several pathophysiologic mechanisms; some 
may be primarily thrombotic, others may be the result of atherosclerosis, and still others 
may be the result of an ongoing inflammatory process (vasculitis). However, in many 
instances, atherosclerosis and thrombosis are likely to occur together, and it is often 
difficult to exactly determine the underlying pathophysiological mechanisms.  
 
Future perspectives 
From the SLE cohort included 2004 and forward (“SLE 2004+”), we have data on 281 
SLE patients and 281 controls, matched for age, sex and region of living. Carotid 
ultrasound has been performed in all patients and controls. We have preliminary 
analyzed these data, and surprisingly, only IMT, but not the amount of plaques, differed 
between SLE patients and controls (crude data, ongoing analyses). We are now going to 
analyze these data more carefully in subgroups of patients and controls and investigate 
risk factors for atherosclerosis. Prospectively, it will be interesting to do a follow-up of 
these patients to evaluate the prognostic value of baseline IMT/plaques for the 
development of clinical CVD. 
An example of an interesting biomarker worth further investigation is cystatin C both in 
relation to atherosclerosis and future events. A good approach would be to measure 
kidney function with for example iohexol clearance, to be able to evaluate the 
importance of cystatin C as a prognostic marker beyond that of renal function (as 
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discussed above). Unfortunately, we do not have these kinds of measurements in our 
cohort, but it could be something to consider for the future. 
Future studies will also focus on looking into the temporal relationship between 
smoking and aPL, trying to evaluate the possibility of reverse causation. Also, we have 
not investigated whether this relationship is influenced by genetic predisposition, in a 
similar way as the occurrence of autoantibodies in RA. Finally, animal studies in a 
similar design as used by Rubin et al(86), could be considered to evaluate the 
association between this environmental factor and aPL.  
Osteoporosis is a common complication in patients with SLE. In all patients mentioned 
above, “SLE 2004+”, Dual-energy X-ray Absorpitometry (DXA) has been performed, 
and we also have measurements on body composition. A lot of information is gathered 
in these data, which have not yet been analyzed. As osteoporosis has been demonstrated 
to be associated with atherosclerosis, common underlying mechanisms are plausible and 
will be investigated in forthcoming studies. We plan to have cooperation with 
endocrinologists to be able to utilize the information in the best way possible.  
Another project is focusing on circulating microparticles, which to some extent can be 
regarded as surrogate measures of cell populations, which are either activated or subject 
to enhanced apoptosis.  
Other ongoing studies are those focusing on the genetic aspects of SLE, where we will 
continue to work together with geneticists in large international collaborations.   
All taken together, future studies will have different angles of approach further trying to 
elucidate the enigma of the increased risk for CVD in SLE patients. 
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Conclusions 
In this thesis I aimed to discuss the pathogenesis and risk factors for cardiovascular 
disease (CVD) and mortality in Systemic Lupus Erythematosus (SLE), and I conclude 
the following: 
Ø Patients with SLE have a higher mortality rate compared to the normal 
population (SMR 2.4) and CVD is a predominant cause of death 
Ø Except for smoking, traditional risk factors seem to have low impact on the 
cardiovascular mortality (CVM) in SLE. Instead, other predictors such as 
cystatin C, inflammation and endothelial activation seem to predict poor 
outcome. 
Ø In a similar way as for CVM, risk factors for the first cardiovascular event 
(CVE) are represented by smoking and activation of the endothelium, and by the 
presence of antiphospholipid antibodies (aPL).  
Ø Sub-phenotypes of SLE seem to have differentiated risk profiles for CVD and 
mortality, where patients with aSSA/SSB antibodies and/or skin manifestations 
have a better prognosis than patients with more severe organ manifestations. 
Ø Genetic predisposition, represented by a STAT4 risk allele, increases the risk of 
ICVD in SLE patients, where aPL may be one underlying mechanism. 
Ø Smoking is associated with the occurrence of aPL. Whether this is due to the 
ability of smoking to induce these autoantibodies remains to be determined. 
Ø Taken together, genetic predisposition in combination with smoking, 
inflammation, endothelial activation and aPL are major risk factors for CVD and 
mortality in SLE, which may act separately, or in combination by common 
pathophysiological mechanisms, to increase the burden of  CVD in SLE. 
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